£2.7M
Epidarex Capital and the University of Leeds led the Series A round to support the development of next generation anticoagulants.
LT
LUNAC Therapeutics
LUNAC Therapeutics develops advanced anticoagulants targeting activated Factor XII.
£2.7MTotal raised
LUNAC Therapeutics is a drug discovery company developing next generation anticoagulants designed to minimise bleeding risk. The firm emerged as a spin out from the University of Leeds.
Categories
Founders
Helen Philippou
Scientific Founder
Helen is the chief executive officer of ClotProtect Therapeutics and co-founder director of Lunac Therapeutics. She also serves as chair of the International Society of Fibrinolysis and Proteolysis and professor of translational medicine at the University of Leeds.
LinkedInRF
Richard Foster